First safety study of MDMA-assisted psychotherapy in patients with alcohol use disorder

Read the full paper here (open access) We present the preliminary data in the Bristol-Imperial MDMA-for-Alcoholism (BIMA) study, an ongoing open-label safety and tolerability proof of concept study exploring the potential role for 3,4-methylenedioxymethamphetamine (MDMA)-assisted psychotherapy in treating patients with alcohol use disorder (AUD). At this stage, eleven participants have completed the full 8-week MDMA-assisted  …


Harms of nicotine-containing products

Around the world, politicians are working to ban e-cigarette marketing, limit their nicotine content, prohibit use in public buildings, and even to ban them entirely. There remains a need for policy makers to become better informed of the relative harms of nicotine delivery systems in order to build a regulatory framework that minimises harm. The  …


DrugScience ketamine review

The first comprehensive review of the drug since its classification, DrugScience’s ketamine review highlighted harms such as neurological and bladder damage. Read it here


Drug harms in the UK

An assessment of the various harms of drugs used recreationally in the UK using multi-criteria decision analysis (MCDA) – a method that uses relevant experts’ knowledge and experience to assess the actual and relative harms – download the paper here. You can also download the raw data here. We wanted to assess drugs in terms  …